Ocular Therapeutix, Inc. (OCUL) vs Trevi Therapeutics, Inc. (TRVI)

Ocular Therapeutix, Inc. and Trevi Therapeutics, Inc. are both Biotechnology companies. Ocular Therapeutix, Inc. and Trevi Therapeutics, Inc. are of similar size ($2.2B and $2.1B). Trevi Therapeutics, Inc. has the higher net margin (0.00% vs −579.1%) and the lower return on invested capital (−1,412.1% vs 0.00%). Across the 14 metrics below, Trevi Therapeutics, Inc. leads on 10 and Ocular Therapeutix, Inc. on 4.

Valuation

Metric OCUL TRVI Biotechnology median
P/E n/m n/m 7.88
P/S 41.70 n/m 11.47
P/B 4.17 7.02 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 31.60 n/m 10.73
Earnings yield (14.72%) (2.36%) (28.84%)
Free cash flow yield (11.75%) (2.34%) (23.03%)

Profitability

Metric OCUL TRVI Biotechnology median
Gross margin 87.11% 0.00% 65.16%
Operating margin (603.04%) 0.00% 0.00%
Net margin (579.10%) 0.00% 0.00%
Free cash flow margin (490.07%) 0.00% 0.00%
Return on equity (72.99%) (19.66%) (57.72%)
Return on assets (53.70%) (18.97%) (49.22%)
Return on invested capital 0.00% (1,412.11%) 0.00%

Growth

Metric OCUL TRVI Biotechnology median
Revenue growth (TTM) (8.14%) — 5.64%
EPS growth (last fiscal year) (16.39%) 31.91% —
Revenue growth, 5-year CAGR 24.45% — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric OCUL TRVI Biotechnology median
Debt to equity 0.14 0.00 0.00
Current ratio 13.11 37.28 4.73
Net debt to EBITDA 2.51 3.83 0.96

Dividend

Metric OCUL TRVI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric OCUL TRVI Biotechnology median
Market cap 2.16b 2.09b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack